Syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients with limited stage small cell lung cancer

被引:43
作者
Tai, Patricia [1 ]
Yu, Edward
Jones, Kurian
Sadikov, Evgeny
Mahmood, Shazia
Tonita, Jon
机构
[1] Univ Saskatchewan, Fac Med, Saskatoon, SK, Canada
[2] Allan Blair Canc Ctr, Dept Radiat Oncol, Regina, SK S4T 7T1, Canada
[3] Univ Western Ontario, Dept Oncol, Div Radiat Oncol, London, ON N6A 4L6, Canada
[4] Saskatchewan Canc Agcy, Dept Epidemiol, Regina, SK S4S 6X3, Canada
关键词
small cell lung cancer; survival; population database; paraneoplastic syndrome; SIADH;
D O I
10.1016/j.lungcan.2006.05.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A few series in the literature were published before 1987 on syndrome of inappropriate antidiuretic hormone secretion (SIADH) in small cell lung cancer (SCLC). This study examines the outcome in more recent era. From 1981-1998, there were 1417 new cases of SCLC diagnosed in the provincial registry, of which 244 were of limited stage (LS). A chart review and statistical analyses were performed using Mann-Whitney test, chi-square test and Kaplan-Meier method. Fourteen LS patients (group A) had SIADH at presentation. Group B consisted of 230 LS patients without SIADH. There were more patients with poorer performance status (ECOG 2-4) in group A than 8 (28.6% versus 7.8%, P = 0.03). Otherwise, sex, age at diagnosis, nodal spread, pleural effusion, bronchial obstruction, superior vena cava obstruction, performance status, weight toss, and tactic dehydrogenase at presentation, were comparable between the two groups. Treatments given, e.g., extent of surgical resection (if performed, whether complete/incomplete), total number of chemotherapy cycles, radiotherapy doses, were comparable (P > 0.05). The response to chemo-radiation was not significantly different (P = 0.7). Five-year overall survival (8% versus 19%, P = 0.08), and cause-specific survival (16% versus 20%, P = 0.13) showed that group A patients had a worse outcome, though of borderline significance. Symptoms related to SIADH included: weakness, 4 patients; tiredness, 3; change in level of consciousness, 1; seizure, 1. The range of lowest sodium level was 110-129. Two patients also had paraneoplastic myopathy. SIADH resolved in 12 patients at 1.6-44.7 weeks (median: 4.3). Among the 14 patients who initially presented with SIADH and recurred later, 10 had recurrence of SIADH at the time of tumor recurrence. Serum sodium was useful for post-treatment surveillance in SCLC patients who presented with SIADH, with 71% (10/14) developing SIADH again at the time of recurrence. SIADH is a poor prognostic factor for LS SCLC. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:211 / 215
页数:5
相关论文
共 13 条
[1]   SMALL CELL-CARCINOMA - COMBINED APPROACH TO TREATMENT [J].
GREGOR, A ;
MORGAN, PGM ;
MORGAN, RL ;
SCADDING, FH ;
TURNERWARWICK, M .
THORAX, 1979, 34 (06) :789-793
[2]  
HAINSWORTH JD, 1983, CANCER, V51, P161, DOI 10.1002/1097-0142(19830101)51:1<161::AID-CNCR2820510131>3.0.CO
[3]  
2-P
[4]  
Hall EJ, 1994, RADIOBIOLOGY RADIOLO, P223
[5]  
HARPER PG, 1982, CANCER TREAT REP, V66, P463
[6]   THE SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC-HORMONE (SIADH) IN SMALL-CELL LUNG-CANCER [J].
LIST, AF ;
HAINSWORTH, JD ;
DAVIS, BW ;
HANDE, KR ;
GRECO, FA ;
JOHNSON, DH .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (08) :1191-1198
[7]  
LOCKTON JA, 1986, CLIN RADIOL, V37, P47
[8]  
LOKICH JJ, 1982, CANCER, V50, P2111, DOI 10.1002/1097-0142(19821115)50:10<2111::AID-CNCR2820501023>3.0.CO
[9]  
2-O
[10]   Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up [J].
Sundstrom, S ;
Bremnes, RM ;
Kaasa, S ;
Aasebo, U ;
Hatlevoll, R ;
Dahle, R ;
Boye, N ;
Wang, M ;
Vigander, T ;
Vilsvik, J ;
Skovlund, E ;
Hannisdal, E ;
Aamdal, S .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4665-4672